Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience

Heianna, Joichi; Toita, Takafumi; Endo, Wataru; Kasuya, Goro; Ariga, Toshio; Hashimoto, Seiji; Maemoto, Hitoshi; Terui, Kazuyuki; Miura, Naoki; Togashi, Aki; Miyauchi, Takaharu; Murayama, Sadayuki

doi:10.1007/s12149-015-1010-6

Cited by 10 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In combination, however, the results are controversial. The pain relief was higher in patients receiving both [ 89 Sr]SrCl and EBRT compared to [ 89 Sr]SrCl-alone in one study [ 48 ], while there was no impact of the addition of [ 89 Sr]SrCl in another [ 49 ].…”

Section: [89 Sr]strontium-dichloride ([ 89 Sr]mentioning

confidence: 99%

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain

Manafi‐Farid

Masoumi

Divband

et al. 2020

JCM

View full text Add to dashboard Cite

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other therapies. Several β¯- and α-emitters as well as pharmaceuticals, from the very first [89Sr]strontium-dichloride to recently introduced [223Ra]radium-dichloride, are investigated to identify an optimum agent. In addition, the combination of bone-seeking radiopharmaceuticals with chemotherapy or radiotherapy has been employed to enhance the outcome. Radiopharmaceuticals demonstrate an acceptable response rate in pain relief. Nevertheless, survival benefits have been documented in only a limited number of studies. In this review, we provide an overview of bone-seeking radiopharmaceuticals used for bone-pain palliation, their effectiveness and toxicity, as well as the results of the combination with other therapies. Bone-pain palliation with radiopharmaceuticals has been employed for eight decades. However, there are still new aspects yet to be established.

show abstract

Section: [89 Sr]strontium-dichloride ([ 89 Sr]mentioning

confidence: 99%

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain

Manafi‐Farid

Masoumi

Divband

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…В любом случае все эти действия носят исключительно симптоматический характер и существенно не влияют на общую выживаемость больных КРРПЖ. Помимо этого, имеется ограничение использования радионуклидной терапии у пациентов с так называемым суперсканом при остеосцинтиграфии во избежание необратимой миелосупрессии [17].…”

Section: Introductionunclassified

Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait

et al. 2019

View full text Add to dashboard Cite

Контакты: Василий Николаевич Ощепков basile-os@yandex.ruПервый и в настоящий момент единственный препарат из группы . По данным плацебоконтролируемых рандомизированных исследований, у пациентов с кастрационно-рефрактерным раком предстательной железы при наличии костных метастазов и отсутствии висцерального распространения применение 223 Ra увеличивает показатели общей выживаемости, период до развития костных осложнений и существенно улучшает качество жизни. Имеющиеся данные свидетельствуют о целесообразности раннего применения 223 Ra в сочетании с энзалутамидом или абиратероном у больных кастрационно-рефрактерным раком предстательной железы с костными метастазами до начала лечения таксанами. На сегодняшний день остается нерешенным вопрос о встраивании современной нуклидной терапии в принятую систему лечения пациентов с кастрационно-резистентным раком предстательной железы.Ключевые слова: кастрационно-резистентный рак предстательной железы, костный метастаз, боль, радий-223, стронций-89, самарий-153, абиратерон, энзалутамид, доцетаксел, общая выживаемость Для цитирования: Ощепков В.Н., Зотов П.Б., Исмаков Р.М. и др. Нуклидная терапия 223-радия хлоридом. Штрихи к портрету пациента. Онкоурология 2018;14(4):87-94.Radium-223 is the 1 st nuclide medicine from the group of alpha emitters, its use is associated with an increase in overall survival, a delay to bone complications and a significant improvement the quality of life, proven placebo-controlled randomized studies in patients with castrationresistant prostate cancer in the presence of bone metastases and no visceral ones. Perhaps the еarly use of radium-223 in combination with enzalutamide or abiraterone in castration-resistant prostate cancer patients with bone metastases, before the start of treatment with taxanes is reasonable.Today, the issue of embedding modern nuclide therapy in the accepted system of treating castration-resistant prostate cancer.For citation : Oschepkov V.N., Zotov P.B., Ismakov R.M. et al. Radionuclide therapy with radium-223 chloride. A few strokes to the patient's portrait. Onko urologiya = Cancer Urology 2018;14(4):87-94.

show abstract